WideMed Rises Most in Three Weeks on Canada Marketing Approval

Oct. 5 (Bloomberg) -- WideMed Ltd. advanced the most in almost three weeks after it said it received approval from Canada to market its Morpheus cardio-sleep analysis product.

The shares gained 8.3 percent, the biggest intraday jump since Sept. 18, to 0.484 shekel at 12:57 p.m. in Tel Aviv.

--Editors: Shanthy Nambiar, Peter Branton

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net